-
摘要: 肠道微生物群（gut microbiota，GM）由数以万亿计的细菌、真菌、古细菌、寄生虫和病毒等组成，GM在机体内部和个体之间的组成因人而异，与饮食习惯、种族、宿主遗传、年龄和既往药物使用情况相关，并参与代谢、炎症、免疫和肿瘤等病理生理功能。GM作为肿瘤潜在生物标志物的作用及其对癌症支持治疗的安全性、耐受性和疗效具有重要临床意义。GM和癌症的关系复杂而密切，可作为生物标记物、诊断工具、治疗靶点，是癌症精准治疗中不可或缺的因素。其不仅对结直肠癌、胃癌等消化道肿瘤具有调节、诊断预测作用，也能在其他系统的恶性肿瘤如肺癌起到生物标志物作用；提高GM的多样性，减少抗生素的使用，降低有害菌群的丰度能有效提高肿瘤的预后、抗肿瘤治疗的疗效。本文旨在对GM在恶性肿瘤发生发展、放化疗的疗效和不良反应、免疫治疗的疗效与不良反应以及饮食通过GM对肿瘤的影响进行总结，为GM的精准化调控和检测对未来肿瘤治疗、肿瘤预测提供参考方向。Abstract: Gut microbiota (GM) are composed of trillions of bacteria, fungi, archaea, parasites, and viruses. The composition of GM varies among individuals; is related to habits, race, genetics, age, and previous drug use; and participates in physiological functions such as metabolism, inflammation, immunity, and tumor suppression. The potential role of GM as a tumor biomarker is clinically significant for the safety, tolerability, and efficacy of supportive cancer therapy. The relationship between GM and cancer is complex and close. GM can be used as a biomarker, diagnostic tool, or therapeutic target. GM are indispensable in the direct treatment of cancer and can regulate, diagnose, and prognosticate gastrointestinal tumors, including colorectal cancer and gastric cancer, and may also act as a biomarker for malignant tumors of other organ systems such as lung cancer. Improving the diversity of GM, reducing antibiotic use, and decreasing the abundance of harmful GM may effectively improve the prognosis of tumors and the efficacy of antitumor therapies. The study aimed to summarize the role of GM in the prevalence and development of malignant tumors; the efficacy and side effects of radiotherapy, chemotherapy, and immunotherapy; and the effect of diet (and subsequently GM) on tumors in order to lay the foundation for future research into the accurate regulation and detection of GM in both the treatment and prognostication of tumors.
-
Key words:
- gut microbiota (GM) /
- supportive therapy /
- malignant tumor
-
[1] Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? revisiting the ratio of bacterial to host cells in humans[J]. Cell, 2016, 164(3):337-340. doi: 10.1016/j.cell.2016.01.013 [2] Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota[J]. Nature, 2012, 489(7415):220-230. doi: 10.1038/nature11550 [3] Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health[J]. Nutrients, 2014, 7(1):17-44. doi: 10.3390/nu7010017 [4] Imhann F, Vich Vila A, Bonder MJ, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota[J]. Gut Microbes, 2017, 8(4):351-358. doi: 10.1080/19490976.2017.1284732 [5] Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier[J]. Gut, 2016, 65(2):330-339. doi: 10.1136/gutjnl-2015-309990 [6] Thomas S, Izard J, Walsh E, et al. The host microbiome regulates and maintains human health: a primer and perspective for non-microbiologists[J]. Cancer Res, 2017, 77(8):1783-1812. doi: 10.1158/0008-5472.CAN-16-2929 [7] Fessler J, Matson V, Gajewski TF. Exploring the emerging role of the microbiome in cancer immunotherapy[J]. J Immunother Cancer, 2019, 7(1):108. doi: 10.1186/s40425-019-0574-4 [8] Scott AJ, Alexander JL, Merrifield CA, et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis[J]. Gut, 2019, 68(9):1624-1632. doi: 10.1136/gutjnl-2019-318556 [9] Lazar V, Ditu LM, Pircalabioru GG, et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer[J]. Front Immunol, 2018, 9:1830. doi: 10.3389/fimmu.2018.01830 [10] Gao ZG, Guo BM, Gao RY, et al. Microbiota disbiosis is associated with colorectal cancer[J]. Front Microbiol, 2015, 6:20. [11] Lu YY, Chen J, Zheng JY, et al. Mucosal adherent bacterial dysbiosis in patients with colorectal adenomas[J]. Sci Rep, 2016, 6:26337. doi: 10.1038/srep26337 [12] Zitvogel L, Galluzzi L, Viaud S, et al. Cancer and the gut microbiota: an unexpected link[J]. Sci Transl Med, 2015, 7(271):271ps1. [13] Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer[J]. Science, 2017, 358(6369):1443-1448. doi: 10.1126/science.aal5240 [14] Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy[J]. Nat Rev Cancer, 2017, 17(5):271-285. doi: 10.1038/nrc.2017.13 [15] Flanagan L, Schmid J, Ebert M, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome[J]. Eur J Clin Microbiol Infect Dis, 2014, 33(8):1381-1390. doi: 10.1007/s10096-014-2081-3 [16] Hong J, Guo FF, Lu SY, et al. F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer[J]. Gut, 2021, 70(11):2123-2137. doi: 10.1136/gutjnl-2020-322780 [17] Dong X, Pan P, Zheng DW, et al. Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer[J]. Sci Adv, 2020, 6(20):eaba1590. doi: 10.1126/sciadv.aba1590 [18] Xia XX, Wu WKK, Wong SH, et al. Bacteria pathogens drive host colonic epithelial cell promoter hypermethylation of tumor suppressor genes in colorectal cancer[J]. Microbiome, 2020, 8(1):108. doi: 10.1186/s40168-020-00847-4 [19] Cammarota G, Ianiro G. Gut microbiota and cancer patients: A broad-ranging relationship[J]. Mayo Clin Proc, 2017, 92(11):1605-1607. doi: 10.1016/j.mayocp.2017.09.009 [20] Coker OO, Wu WKK, Wong SH, et al. Altered gut Archaea composition and interaction with bacteria are associated with colorectal cancer[J]. Gastroenterology, 2020, 159(4):1459-1470. doi: 10.1053/j.gastro.2020.06.042 [21] Xiao Q, Lu W, Kong XX, et al. Alterations of circulating bacterial DNA in colorectal cancer and adenoma: a proof-of-concept study[J]. Cancer Lett, 2021, 499:201-208. doi: 10.1016/j.canlet.2020.11.030 [22] Zheng YJ, Fang ZY, Xue Y, et al. Specific gut microbiome signature predicts the early-stage lung cancer[J]. Gut Microbes, 2020, 11(4):1030-1042. [23] Zhang S, Kong C, Yang YZ, et al. Human oral microbiome dysbiosis as a novel non-invasive biomarker in detection of colorectal cancer[J]. Theranostics, 2020, 10(25):11595-11606. doi: 10.7150/thno.49515 [24] Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(6):356-365. doi: 10.1038/nrgastro.2017.20 [25] Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J]. Science, 2013, 342(6161):971-976. doi: 10.1126/science.1240537 [26] Daillère R, Vétizou M, Waldschmitt N, et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects[J]. Immunity, 2016, 45(4):931-943. [27] Yu T, Guo FF, Yu YN, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J]. Cell, 2017, 170(3):548-563. doi: 10.1016/j.cell.2017.07.008 [28] Wardill HR, Gibson RJ, van Sebille YZ, et al. Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms[J]. Mol Cancer Ther, 2016, 15(6):1376-1386. [29] Nakayama H, Kinouchi T, Kataoka K, et al. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil[J]. Pharmacogenetics, 1997, 7(1):35-43. doi: 10.1097/00008571-199702000-00005 [30] Fijlstra M, Ferdous M, Koning AM, et al. Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model[J]. Support Care Cancer, 2015, 23(6):1513-1522. doi: 10.1007/s00520-014-2487-6 [31] Gerassy-Vainberg S, Blatt A, Danin-Poleg Y, et al. Radiation induces proinflammatory dysbiosis: transmission of inflammatory susceptibility by host cytokine induction[J]. Gut, 2018, 67(1):97-107. doi: 10.1136/gutjnl-2017-313789 [32] Cui M, Xiao HW, Li Y, et al. Faecal microbiota transplantation protects against radiation-induced toxicity[J]. EMBO Mol Med, 2017, 9(4):448-461. doi: 10.15252/emmm.201606932 [33] Luo XX, Yang C, Zhan GF, et al. Whole brain radiotherapy induces cognitive dysfunction in mice: key role of gut microbiota[J]. Psychopharmacology (Berl), 2020, 237(7):2089-2101. doi: 10.1007/s00213-020-05520-0 [34] Yi YX, Shen LJ, Shi W, et al. Gut microbiome components predict response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a prospective, longitudinal study[J]. Clin Cancer Res, 2021, 27(5):1329-1340. doi: 10.1158/1078-0432.CCR-20-3445 [35] Mager LF, Burkhard R, Pett N, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy[J]. Science, 2020, 369(6510):1481-1489. doi: 10.1126/science.abc3421 [36] Tomita Y, Ikeda T, Sakata S, et al. Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer[J]. Cancer Immunol Res, 2020, 8(10):1236-1242. doi: 10.1158/2326-6066.CIR-20-0051 [37] Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials[J]. Ann Oncol, 2020, 31(4):525-531. doi: 10.1016/j.annonc.2020.01.006 [38] Hopkins AM, Kichenadasse G, Karapetis CS, et al. Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab[J]. Clin Cancer Res, 2020, 26(20):5487-5493. [39] Jin YP, Dong H, Xia LL, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC[J]. J Thorac Oncol, 2019, 14(8):1378-1389. doi: 10.1016/j.jtho.2019.04.007 [40] Peng Z, Cheng SY, Kou Y, et al. The gut microbiome is associated with clinical response to anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer[J]. Cancer Immunol Res, 2020, 8(10):1251-1261. [41] Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients[J]. Science, 2021, 371(6529):602-609. [42] Routy B, le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J].Science, 2018, 359(6371):91-97. [43] Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018, 359(6371):97-103. doi: 10.1126/science.aan4236 [44] Ji XL, Hou CY, Gao YG, et al. Metagenomic analysis of gut microbiota modulatory effects of jujube (Ziziphus jujuba Mill. ) polysaccharides in a colorectal cancer mouse model[J]. Food Funct, 2020, 11(1):163-173. doi: 10.1039/C9FO02171J [45] Zheng DW, Li RQ, An JX, et al. Prebiotics-encapsulated probiotic spores regulate gut microbiota and suppress colon cancer[J]. Adv Mater, 2020, 32(45):e2004529. doi: 10.1002/adma.202004529 -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 236
- HTML全文浏览量: 76
- PDF下载量: 53
- 被引次数: 0
